Меню
Идёт набор NCT06915701

"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"

Фаза II / Фаза III С лечением Rheumatoid Arthritis

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Will take vitamin E 800mg/day, Will take 200mg/day magnesium oxide placebo..
Кому может быть актуально
Состояния в реестре: Rheumatoid Arthritis. Базовые параметры: от 18 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Мексика
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

"Evaluation of the Effect of Vitamin E (α-tocopherol) Supplementation on Clinical Activity and Inflammation in Patients With Rheumatoid Arthritis"

Обзор

The objective of this clinical trial is to determine whether α-tocopherol (vitamin E) supplementation decreases inflammation and clinical activity in patients with rheumatoid arthritis (RA).The main questions to be answered are: * Is supplementation with vitamin E (α-tocopherol) for one month associated with decreased clinical activity and inflammation in patients with RA? Researchers will compare α-tocopherol with a placebo (a look-alike substance containing no active ingredient) to see if α-tocopherol effectively reduces inflammation and clinical activity in patients with rheumatoid arthritis. Participants will: * Take two capsules (one in the morning and one in the afternoon) of either α-tocopherol or placebo every day for a month. * Attend clinic visits at the start of the intervention (baseline) and at the end of the month for final check-ups and tests. * Keep a diary to record your symptoms and how often you take α-tocopherol or placebo.

Подробное описание

Background:

Rheumatoid arthritis (RA) RA is one of the most common autoimmune diseases, characterized by chronic inflammation of the sinovia, mainly of the small joints of the hand, wrists and feet. Chronic inflammation can lead to the destruction of cartilage and joint bone, causing joint deformity, functional disability, depression and significant economic costs for the affected individual.

α-tocopherol acetate: The α-tocopherol acetate is the most widely used analogue in food supplements because of its esterification gives it stability. The main function is antioxidant preventing lipid oxidation of cell membranes for this reason α-tocopherol is considered a possible protector against diseases related to oxidative processes such as chronic diseasedegenerative diseases such as diabetes mellitus, cancer, cardiovascular disease, rheumatic disease, neurological disease and ageing.

Vitamin E in RA: The role of vitamin E as a therapy in combination with RA treatment has been studied in several studies. Studies in mouse models of laminarin-induced arthritis have shown that supplementation with α-tocopherol decreases the expression of pro-inflammatory cytokines such as IL-6, TNF-α and MMPs. However, the mechanisms involved are unknown. There are few studies in RA patients where the effect of supplementation with α-tocopherol has been analyzed. In clinical trials, it has been observed that from 3 weeks with supplementation of α-tocopherol decreases the scales of clinical activity in addition to morning stiffness and joint pain even biochemical parameters such as acute phase reactants such as pCr and ESR. However, the effect on pro-inflammatory cytokines, autoantibodies and antioxidant effect has not been analyzed.

Research question: Is supplementation with Vitamin E (α-tocopherol) for one month associated with decreased clinical activity and inflammation in patients with RA?

Specific objectives

1. Analyze the clinical characteristics and diet quality of RA patients 2. Determine serum autoantibody levels in RA patients 3. Quantify serum vitamin E levels before and after supplementation in both study groups (Vitamin E and placebo) 4. Compare clinical activity before and after supplementation in both study groups 5. Quantify serum concentration of pro-inflammatory cytokines IL1β, IL6 and TNF-α before and after supplementation in both study groups 6. Determine antioxidant capacity before and after supplementation in both study groups 7. Associate vitamin E levels with clinical and inflammatory parameters of patients with RA

Hypothesis :

There is an association between supplementation with vitamin E (α-tocopherol) and decreased clinical activity and inflammation in patients with RA from western Mexico

Methodological design:

a) Study type - Clinical, randomized, controlled and double-blind trial.

Research sites:

* Institute of Biomedical Sciences (IICB) of the University Center for Health Sciences (CUCS) * Laboratory for Clinical Analysis and Translational Research (LACIT), at the University Center for Exact Sciences and Engineering (CUCEI) * Rheumatology Service of the Civil Hospital "Fray Antonio Alcalde" in Guadalajara, Jalisco.

Time to develop: January 2025 to January 2027.

Sample size:

The statistical formula of two averages was used for the calculation of the sample size. The calculations were made with data from the corresponding 2001 clinical trial of Mona Helmy and colleagues, resulting in a sample size of 19 patients plus an increase of 20% to cover possible losses. Having 23 patients for control and intervention group. Both groups with RA of the Rheumatology Service of the Civil Hospital "Fray Antonio Alcalde" in Guadalajara, Jalisco.

Variables Independent variables

* Vitamin E Dependent variables * Inflammatory cytokines (IL-1β, IL-6 and TNF-α). Antioxidant capacity:( DPPH, ABTS, FRAP and ORAC). Clinical evolution: DAS-28. Acute phase reactants: pCr and ESR. Auto-antibodies: Anti-ccp and rheumatoid factor.

Biosafety considerations:

This study will apply the guidelines set out in the Mexican Official Standards, NOM-052-SEMARNAT-2005, NOM-054-SEMARNAT-1993 and NOM-087-ECOL-SSA1-2002 that refer to classification, Handling, storage and disposal of hazardous waste, chemical reagents and biological-infectious wastes, in order to ensure the protection of people in contact with them and the environment.

Ethical considerations:

The project will be carried out in accordance with the ethical standards and principles for medical research on human beings, as set out in the Declaration of Helsinki, which were last reviewed at the 64th General Assembly, Fortaleza, Brazil, October 2013, which refers to ethical principles for medical research in humans.

Вмешательства

  • Пищевая добавка Will take vitamin E 800mg/day
    Patients with deficient vitamin E intake (\<15mg/day), who are treated with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) plus vitamin E 800mg/day.
  • Препарат Will take 200mg/day magnesium oxide placebo.
    Patients with RA deficient in vitamin E intake (\<15mg/day) , who are treated with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) plus the consumption of magnesium oxide 200mg/day in placebo form.

Первичные конечные точки

  • Levels of vitamin E [Срок оценки: Exchange measures: Baseline and 1 month.]
Вторичные конечные точки (8)
  • Twenty-four hour reminder "questionnaire" (Recommended Daily Intake of Vitamin E) [Срок оценки: Exchange measures: Baseline and 1 month.]
  • Levels of: Proinflammatory cytokines ( IL-1β , IL-6 and TNF-α ) [Срок оценки: Exchange measures: Baseline and 1 month.]
  • Antioxidant capacity: (DPPH, ABTS, FRAP and ORAC) [Срок оценки: Exchange measures: Baseline and 1 month.]
  • Index DAS-28 [Срок оценки: Exchange measures: Baseline and 1 month.]
  • C-reactive protein (pCr) [Срок оценки: Exchange measures: Baseline and 1 month.]
  • Erythrocyte sedimentation rate (ESR) [Срок оценки: Exchange measures: Baseline and 1 month.]
  • Auto- antibodies: Anti-CCP [Срок оценки: Exchange measures: Baseline and 1 month.]
  • Rheumatoid factor [Срок оценки: Exchange measures: Baseline and 1 month.]

Критерии участия

Критерии включения

  • Female sex
  • RA classification (ACR/EULAR 2010)
  • Early RA 2 years
  • Treatment with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations)
  • DAS28 ≥3.2
  • Vitamin E intake deficiency (<15mg/day)
  • No comorbidities
  • Age > 18 years
  • Voluntary participation and informed consent.

Критерии исключения

  • Liver and kidney disease
  • Overlap syndrome
  • Coagulation disorders
  • Pregnancy
  • Consumption of supplements (iron, vitamin E, and K), and medications such as acetylsalicylic acid, amlodipine, estrogen, glucocorticoids and drugs used to treat dyslipidemias in the last three months.

Elimination Criteria:

  • Errors in administration of the 20% supplement
  • Adverse effects of the supplement
  • Pregnancy during the study
  • Insufficient blood sample
  • Voluntary withdrawal of informed consent.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Двойное слепое
Основная цель
Лечение

Центры проведения

Мексика · 2 центра
  • Civil Hospital of Guadalajara — Guadalajara
  • Universidad de Guadalajara — Guadalajara

Публикации

  • Kim KW, Kim BM, Won JY, Min HK, Lee SJ, Lee SH, Kim HR. Tocotrienol regulates osteoclastogenesis in rheumatoid arthritis. Korean J Intern Med. 2021 Mar;36(Suppl 1):S273-S282. doi: 10.3904/kjim.2019.372. Epub 2020 Jun 19. PMID 32550719
  • Hama S, Kirimura N, Obara A, Takatsu H, Kogure K. Tocopheryl Phosphate Inhibits Rheumatoid Arthritis-Related Gene Expression In Vitro and Ameliorates Arthritic Symptoms in Mice. Molecules. 2022 Feb 20;27(4):1425. doi: 10.3390/molecules27041425. PMID 35209214
  • Al-Okbi SY. Nutraceuticals of anti-inflammatory activity as complementary therapy for rheumatoid arthritis. Toxicol Ind Health. 2014 Sep;30(8):738-49. doi: 10.1177/0748233712462468. Epub 2012 Oct 26. PMID 23104728
  • Zhang T, Yi X, Li J, Zheng X, Xu H, Liao D, Ai J. Vitamin E intake and multiple health outcomes: an umbrella review. Front Public Health. 2023 Jul 13;11:1035674. doi: 10.3389/fpubh.2023.1035674. eCollection 2023. PMID 37522003
  • Glowka AK, Kowalowka M, Burchardt P, Komosa A, Kruszyna L, Andrusiewicz M, Przyslawski J, Karazniewicz-Lada M. Selected Psychosocial Factors, Nutritional Behavior, and the Analysis of Concentrations of Selected Vitamins in Patients with Cardiovascular Diseases. Nutrients. 2024 Jun 14;16(12):1866. doi: 10.3390/nu16121866. PMID 38931221
  • Galli F, Azzi A, Birringer M, Cook-Mills JM, Eggersdorfer M, Frank J, Cruciani G, Lorkowski S, Ozer NK. Vitamin E: Emerging aspects and new directions. Free Radic Biol Med. 2017 Jan;102:16-36. doi: 10.1016/j.freeradbiomed.2016.09.017. Epub 2016 Nov 2. PMID 27816611
  • Lewis ED, Meydani SN, Wu D. Regulatory role of vitamin E in the immune system and inflammation. IUBMB Life. 2019 Apr;71(4):487-494. doi: 10.1002/iub.1976. Epub 2018 Nov 30. PMID 30501009
  • Kemnic TR, Coleman M. Vitamin E Deficiency. 2023 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK519051/ PMID 30085593

Идентификаторы

NCT: NCT06915701 · CEI A-176/24

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗